Growth factors and epithelial-stromal interactions in prostate cancer development

doi:10.1016/S0074-7696(00)99002-8

International Review of Cytology

Volume 199, 2000, Pages 65-116

https://doi.org/10.1016/S0074-7696(00)99002-8 Get rights and content

Abstract

Epithelial-stromal interactions are important not only in growth, development, and functional cytodifferentiation of the prostate but also in derangements of prostate gland such as BPH and prostate carcinoma. This chapter explores the roles of epithelium and stroma during this delicate process and highlights the role and mutual influence of each on the other. It also examines the importance of ECM in mediating the effects of androgens and drawn attention to estrogen and genetic factors in the process. During this process of epithelial-stromal interaction, growth factors play a central role in mediating the interactions. This chapter focuses on the role of several growth factors including epidermal growth factor, fibroblast growth factor, transforming growth factor alpha, transforming growth factor beta, insulin-like growth factor-1, vascular endothelial growth factor, nerve growth factor, platelet-derived growth factor, and hepatocyte growth factor. This chapter emphasizes the importance of epithelial-stromal interactions in tumorigenesis and highlights the switch of paracrine to autocrine mode during the process of carcinogenesis.

References (251)

F.P Begun et al.
Regional concentration of basic fibroblast growth factor in normal and benign hyperplastic human prostates
J. Urol.
(1995)
L.F Brown et al.
Vascular permeability factor (vascular endothelial growth factor) is strongly expressed in the normal male genital tract and is present in substantial quantities in semen
J. Urol.
(1995)
S Cheifetz et al.
Distinct transforming growth factor-beta (TGF-beta) receptor subsets as determinants of cellular responsiveness to three TGF-beta isoforms
J. Biol. Chem.
(1990)
J.M Connolly et al.
Angiogenesis in two human prostate cancer cell lines with differing metastatic potential when growing as solid tumors in nude mice
J. Urol.
(1998)
D.E Davies et al.
Targeting the epidermal growth factor receptor for therapy of carcinomas
Biochem. Pharmacol.
(1996)
A.M De Marzo et al.
E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens
Urology
(1999)
R Derynck
Transforming growth factor alpha
Cell
(1988)
A.A Donjacour et al.
Enlargement of the ampullary gland and seminal vesicle, but not the prostate in int-2/Fgf-3 transgenic mice
Differentiation
(1998)
J.E Fowler et al.
Epidermal growth factor and prostatic carcinoma: an immunohistochemical study
J. Urol.
(1988)
P.E Gleason et al.
Platelet derived growth factor (PDGF), androgens and inflammation: Possible etiologic factors in the development of prostatic hyperplasia
J. Urol.
(1993)

E Glynne-Jones et al.

Comparative analysis of mRNA and protein expression for epidermal growth factor receptor and ligands relative to the proliferative index in human prostate tissue

Hum. Pathol.

(1996)

C.W Graham et al.

Distribution of nerve growth factorlike protein and nerve growth factor receptor in human benign prostatic hyperplasia and prostatic adenocarcinoma

J. Urol.

(1992)

S.W Hayward et al.

Interactions between adult human prostatic epithelium and rat urogenital sinus mesenchyme in a tissue recombination model

Differentiation

(1998)

W.W He et al.

A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer

Genomics

(1997)

H.B Heidenberg et al.

Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer

J. Urol.

(1995)

T Helting et al.

Biosynthesis of chondroitin sulphate. I. Galactosyl transfer in the formation of the carbohydrate-protein linkage region

J. Biol. Chem.

(1969)

M.T Hierowski et al.

The partial dependency of human prostatic growth factor on steroid hormones in stimulating thymidine incorporation into DNA

J. Urol.

(1987)

G.M Abu-Jawdeh et al.

Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms

Lab. Invest.

(1996)

M.D Balbay et al.

Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor

Clin. Cancer Res.

(1999)

L Bao et al.

Thymosin beta 15:Anovel regulator of tumor cell motility upregulated in metastatic prostate cancer

Nat. Med.

(1996)

E.R Barrack

TGF beta in prostate cancer: A growth inhibitor that can enhance tumorigenicity

Prostate

(1997)

R Bhatia-Gaur et al.

Roles for nkx3.1 in prostate development and cancer

Genes Dev.

(1999)

M Blaber et al.

X-ray crystal structure of human acidic fibroblast growth factor

Biochemistry

(1996)

R Bookstein et al.

Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene

Science

(1990)

F.T Bosman et al.

Epithelial-stromal interactions in colon cancer

Int. J. Dev. Biol.

(1993)

J.D Brooks et al.

Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas

Prostate

(1995)

J.D Brooks et al.

An uncertain role for p53 gene alterations in human prostate cancers

Cancer Res.

(1996)

L Bubendorf et al.

Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays

Cancer Res.

(1999)

M.J Bussemakers et al.

Decreased expression of E-cadherin in the progression of rat prostatic cancer

Cancer Res.

(1992)

S.M Chang et al.

Interaction between prostatic fibroblast and epithelial cells in culture: Role of androgen

Endocrinology

(1989)

L Cheng et al.

Expression of E-cadherin in primary and metastatic prostate cancer

Am. J. Pathol.

(1996)

M.L Cher et al.

Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping

Cancer Res.

(1996)

K.Z Ching et al.

Expression of mRNA for epidermal growth factor, transforming growth factor-alpha and their receptor in human prostate tissue and cell lines

Mol. Cell Biochem.

(1993)

L.W Chung

The role of stromal-epithelial interaction in normal and malignant growth

Cancer Surv.

(1995)

L.W Chung et al.

Human prostate cancer model: Roles of growth factors and extracellular matrices

J. Cell Biochem. Suppl.

(1992)

D.S Coffey

Prostate cancer metastasis: Talking the walk

Nat. Med.

(1996)

M.M Cohen

Wiedemann-Beckwith syndrome, imprinting, IGF2, and H19: Implications for hemihyperplasia, associated neoplasms, and overgrowth

Am. J. Med. Genet.

(1994)

P Cohen et al.

Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells

J. Clin. Endocrinol. Metab.

(1991)

C.N Coleman et al.

Prostate cancer

M Colombel et al.

Androgen suppressed apoptosis is modified in p53 deficient mice

Oncogene

(1995)

M.S Condon et al.

The role of stromal cells in prostate cancer development and progression

In Vivo

(1999)

J.M Connolly et al.

Secretion of epidermal growth factor and related polypeptides by the DU 145 human prostate cancer cell line

Prostate

(1989)

J.M Coulson et al.

A nonantisense sequence-selective effect of a phosphorothioate oligodeoxynucleotide directed against the epidermal growth factor receptor in A431 cells

Mol. Pharmacol.

(1996)

Z Culig et al.

Regulation of prostatic growth and function by peptide growth factors

Prostate

(1996)

Z Culig et al.

Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor

Cancer Res.

(1994)

G.R Cunha

Mesenchymal-epithelial interactions during androgen-induced development of the prostate

Prog. Clin. Biol. Res.

(1985)

G.R Cunha

Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate

Cancer

(1994)

G.R Cunha et al.

The possible influences of temporal factors in androgenic responsiveness of urogenital tissue recombinants from wild-type and androgen-insensitive (Tfm) mice

J. Exp. Zool.

(1978)

G.R Cunha et al.

Epithelial-mesenchymal interactions in prostatic development. I. Morphological observation of prostatic induction by urogenital sinus mesenchyme in epithelium of the adult rodent urinary bladder

J. Cell. Biol.

(1983)

G.R Cunha et al.

The endocrinology and developmental biology of the prostate

Endocr. Rev.

(1987)

Cited by (83)

Three-dimensional culture systems in cancer research: Focus on tumor spheroid model
2016, Pharmacology and Therapeutics
Citation Excerpt :
Compelling evidence from two decades of research has revealed the critical role of tumor microenvironment (TME) in cancer development and progression (Mbeunkui & Johann, 2009; Quail & Joyce, 2013). The cellular components of the TME (transformed epithelial cells, cancer-associated fibroblasts (CAFs), tumor infiltrating mesenchymal stem cells (MSCs), tumor infiltrating lymphocytes (TILs), and endothelial cells) interact with tumor cells and impact various biological characteristics such as proliferation, migration, and therapeutic resistance (Joyce & Pollard, 2009; Loebinger et al., 2009; Zhu et al., 2009; Wong & Wang, 2000; Baker & Chen, 2012; Quail & Joyce, 2013; Kyurkchiev et al., 2014; Smith & Kang, 2014; Fedorenko & Smalley, 2015; Karakasheva et al., 2015; Yulyana et al., 2015). The non-cellular components of the TME (extracellular matrix (ECM), growth factors, cytokines, and chemokines) play an equally significant role in cancer progression, by presenting cues that affect fundamental aspects of tumor cell biology (Paszek et al., 2005; Levental et al., 2009; Lu et al., 2012).
Cancer cells propagated in three-dimensional (3D) culture systems exhibit physiologically relevant cell–cell and cell–matrix interactions, gene expression and signaling pathway profiles, heterogeneity and structural complexity that reflect in vivo tumors. In recent years, development of various 3D models has improved the study of host–tumor interaction and use of high-throughput screening platforms for anti-cancer drug discovery and development. This review attempts to summarize the various 3D culture systems, with an emphasis on the most well characterized and widely applied model — multicellular tumor spheroids. This review also highlights the various techniques to generate tumor spheroids, methods to characterize them, and its applicability in cancer research.
Stromal androgen receptor in prostate development and cancer
2014, American Journal of Pathology
The androgen receptor (AR) in stromal cells contributes significantly to the development and growth of prostate during fetal stages as well as during prostate carcinogenesis and cancer progression. During prostate development, stromal AR induces and promotes epithelial cell growth, as observed from tissue recombinant and mouse knockout studies. During prostate carcinogenesis and progression, the stromal cells begin to lose AR expression as early as at the stage of high-grade prostatic intraepithelial neoplasia. The extent of loss of stromal AR is directly proportional to the degree of differentiation (Gleason grade) and progression of prostate cancer (PCa). Co-culture studies suggested that stromal AR inhibits the growth of malignant epithelial cells, possibly through expression of certain paracrine factors in the presence of androgens. This functional reversal of stromal AR, from growth promotion during fetal prostate development to mediating certain growth-inhibiting effects in cancer, explains to some extent the reason that loss of AR expression in stromal cells may be crucial for development of resistance to androgen ablation therapy for PCa. From a translational perspective, it generates the need to re-examine the current therapeutic options and opens a fundamental new direction for therapeutic interventions, especially in advanced PCa.
Tumor microenvironment and metabolism in prostate cancer
2014, Seminars in Oncology
Prostate cancer is no longer viewed mostly as a disease of abnormally proliferating epithelial cells, but rather as a disease affecting the complex interactions between the cells of the prostate epithelial compartment and the surrounding stromal compartment in which they live. Indeed, the microenvironment in which tumor cells evolve towards an aggressive phenotype is highly heterogeneous, as it is composed of different cell populations such as endothelial cells, fibroblasts, macrophages, and lymphocytes, either resident or trans-differentiated by bone marrow–derived mesenchymal stem cells recruited at the tumor site. Cancer-associated fibroblasts, the most abundant population within this microenvironment, exert a mandatory role in prostate cancer progression as they metabolically sustain cancer cell survival and growth, recruit inflammatory and immune cells, and promote cancer cells stemness and epithelial mesenchymal transition, thereby favoring metastatic dissemination of aggressive cancers. The interruption of this two-compartment crosstalk, together with the idea that stromal cells are mostly vulnerable, being drug-sensitive, could lead to the development of anticancer therapies that target tumor stromal elements.
Oxidative stress in prostate cancer
2009, Cancer Letters
Citation Excerpt :
DHT, synthesized from testosterone in the prostate by 5α-reductase [65], has a more potent effect due to its higher affinity to the androgen receptor (AR). The AR in turn, binds to androgen receptor elements (ARE) present in the promoter regions of many genes involved in cellular proliferation [66]. Traditionally, initial stages of prostate cancer were controlled by Androgen deprivation therapy; however, aberrant AR activity, in prostate tumors finally leads to the development of a highly malignant state of disease unresponsive to androgen control [67].
As prostate cancer and aberrant changes in reactive oxygen species (ROS) become more common with aging, ROS signaling may play an important role in the development and progression of this malignancy. Increased ROS, otherwise known as oxidative stress, is a result of either increased ROS generation or a loss of antioxidant defense mechanisms. Oxidative stress is associated with several pathological conditions including inflammation and infection. ROS are products of normal cellular metabolism and play vital roles in stimulation of signaling pathways in response to changing intra- and extracellular environmental conditions. Chronic increases in ROS over time are known to induce somatic mutations and neoplastic transformation. In this review we summarize the causes for increased ROS generation and its potential role in etiology and progression of prostate cancer.
Long-term effects of developmental exposure to di-n-butyl-phthalate (DBP) on rat prostate: Proliferative and inflammatory disorders and a possible role of androgens
2009, Toxicology
In the present study we evaluated the toxic effects on the male adult rat prostate of DBP exposure during fetal and lactational periods, because although many studies have addressed the influence of phthalates on the male reproductive system, only a few have discussed their possible effects on prostate development. Pregnant females were distributed into two experimental groups: Control (C) and Treated (T). The females of the T group received DBP (100 mg/kg, by gavage) from gestation day 12 to postnatal day 21, while C rats received the vehicle (corn oil). In adulthood (90 days old), the animals were euthanized. The serum and testicular testosterone levels were measured. Ventral prostate was removed and weighed. Distal segment fragments of the ventral prostate were fixed and processed for histochemistry and immunohistochemistry to detect androgen receptor (AR) and Ki67 antigens. Protein extraction from ventral prostate fragments was performed for AR immunoblotting and Gelatin zymography for MMP-2 and MMP-9 (MMP, metalloproteinase). Stereological and histopathological analyses were also performed. Serum and testicular testosterone levels and prostate weight were comparable between groups. In the T group the relative proportions (%) of epithelial (C = 32.86; T = 42.04*) and stromal (C = 21.61; T = 27.88*) compartments were increased, while the luminal compartment was decreased (C = 45.54; T = 30.08*), *p < 0.05. In T, disseminated inflammatory infiltrate in the stroma, associated or not with epithelial dysplasia and PIN (Prostatic Intraepithelial Neoplasia), was observed. Increases in AR expression, proliferation index and metalloproteinase 9 (MMP-9) activity were noted in T animals. In some T animals, collagen fibrils accumulated adjacent to the epithelium. As far as we are aware, this is the first report in the literature showing that phthalates could play a role in proliferative and inflammatory disorders of the rat prostate.
Human prostate stromal cells stimulate increased PSA production in DHEA-treated prostate cancer epithelial cells
2008, Journal of Steroid Biochemistry and Molecular Biology
Dehydroepiandrosterone (DHEA) is commonly used as a dietary supplement and may affect prostate pathophysiology when metabolized to androgens and/or estrogens. Human prostate LAPC-4 cancer cells with a wild type androgen receptor (AR) were treated with DHEA, androgens dihydrotestosterone (DHT), T, or R1881), and E₂ and assayed for prostate specific antigen (PSA) protein and gene expression. In LAPC-4 monocultures, DHEA and E₂ induced little or no increase in PSA protein or mRNA expression compared to androgen-treated cells. When prostate cancer-associated (6S) stromal cells were added in coculture, DHEA stimulated LAPC-4 cell PSA protein secretion to levels approaching induction by DHT. Also, DHEA induced 15-fold more PSA mRNA in LAPC-4 cocultures than in monocultures. LAPC-4 proliferation was increased 2–3-fold when cocultured with 6S stromal cells regardless of hormone treatment. DHEA-treated 6S stromal cells exhibited a dose- and time-dependent increase in T secretion, demonstrating stromal cell metabolism of DHEA to T. Coculture with non-cancerous stroma did not induce LAPC-4 PSA production, suggesting a differential modulation of DHEA effect in a cancer-associated prostate stromal environment. This coculture model provides a research approach to reveal detailed endocrine, intracrine, and paracrine signaling between stromal and epithelial cells that regulate tissue homeostasis within the prostate, and the role of the tumor microenvironment in cancer progression.

View all citing articles on Scopus

View full text

Growth factors and epithelial-stromal interactions in prostate cancer development

Abstract

J. Urol.

J. Urol.

J. Biol. Chem.

J. Urol.

Biochem. Pharmacol.

Urology

Cell

Differentiation

J. Urol.

J. Urol.

Hum. Pathol.

J. Urol.

Differentiation

Genomics

J. Urol.

J. Biol. Chem.

J. Urol.

Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms

Lab. Invest.

Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor

Clin. Cancer Res.

Thymosin beta 15:Anovel regulator of tumor cell motility upregulated in metastatic prostate cancer

Nat. Med.

TGF beta in prostate cancer: A growth inhibitor that can enhance tumorigenicity

Prostate

Roles for nkx3.1 in prostate development and cancer

Genes Dev.

X-ray crystal structure of human acidic fibroblast growth factor

Biochemistry

Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene

Science

Epithelial-stromal interactions in colon cancer

Int. J. Dev. Biol.

Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas

Prostate

An uncertain role for p53 gene alterations in human prostate cancers

Cancer Res.

Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays

Cancer Res.

Decreased expression of E-cadherin in the progression of rat prostatic cancer

Cancer Res.

Interaction between prostatic fibroblast and epithelial cells in culture: Role of androgen

Endocrinology

Expression of E-cadherin in primary and metastatic prostate cancer

Am. J. Pathol.

Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping

Cancer Res.

Expression of mRNA for epidermal growth factor, transforming growth factor-alpha and their receptor in human prostate tissue and cell lines

Mol. Cell Biochem.

The role of stromal-epithelial interaction in normal and malignant growth

Cancer Surv.

Human prostate cancer model: Roles of growth factors and extracellular matrices

J. Cell Biochem. Suppl.

Prostate cancer metastasis: Talking the walk

Nat. Med.

Wiedemann-Beckwith syndrome, imprinting, IGF2, and H19: Implications for hemihyperplasia, associated neoplasms, and overgrowth

Am. J. Med. Genet.

Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells

J. Clin. Endocrinol. Metab.

Prostate cancer

Androgen suppressed apoptosis is modified in p53 deficient mice

Oncogene

The role of stromal cells in prostate cancer development and progression

In Vivo

Secretion of epidermal growth factor and related polypeptides by the DU 145 human prostate cancer cell line

Prostate

A nonantisense sequence-selective effect of a phosphorothioate oligodeoxynucleotide directed against the epidermal growth factor receptor in A431 cells

Mol. Pharmacol.

Regulation of prostatic growth and function by peptide growth factors

Prostate

Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor

Cancer Res.

Mesenchymal-epithelial interactions during androgen-induced development of the prostate

Prog. Clin. Biol. Res.

Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate

Cancer

The possible influences of temporal factors in androgenic responsiveness of urogenital tissue recombinants from wild-type and androgen-insensitive (Tfm) mice

J. Exp. Zool.